26
АНЕСТЕЗИОЛОГИЯ И РЕАНИМАТОЛОГИЯ 2, 2019
113. Johansen M, Wikkelsø A, Lunde J, Wetterslev J, Afshari A. Prothrombin com-
plex concentrate for reversal of vitamin K antagonist treatment in bleeding
and non-bleeding patients.
Cochrane Database Syst Rev. 2015;(7):CD010555.
114. Huber A, Raio L, Alberio L, Ghezzi F, Surbek D.
Recombinant human fac-
tor VIIa prevents hysterectomy in severe postpartum hemorrhage: single cen-
ter study.
J Perinat Med. 2011;40(1):43-49.
115. Phillips L, McLintock C, Pollock W, Gatt S, et al. Australian and New Zea-
land Haemostasis Registry. Recombinant activated factor VII in obstetric
hemorrhage: experiences from the Australian and New Zealand Haemosta-
sis Registry.
Anesth Analg. 2009;109(6):1908-1915.
116. Lavigne-Lissalde G, Aya A, Mercier F,
Roger-Christoph S, et al. Recom-
binant human FVIIa for reducing the need for invasive second-line thera-
pies in severe refractory postpartum hemorrhage: a multicenter, randomized,
open controlled trial.
J Thromb Haemost. 2015;13(4):520-529.
117. Franchini M, Manzato F, Salvagno G, Lippi G.
Potential role of recombi-
nant activated factor VII for the treatment of severe bleeding associated with
disseminated intravascular coagulation: a systematic review.
Blood Coagul Fi-
Достарыңызбен бөлісу: